GLP-1 Drugs Linked to Long-Term Benefits for PAD Patients

GLP-1 drugs linked to long-term benefits for PAD patients

PAD patients treated with GLP-1 receptor agonists lived longer, stayed out of the hospital more and experienced fewer amputations than those given metformin.

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

GLP-1 RAs Linked to Lower Mortality, Amputation Risk in PAD and Type 2 Diabetes

July 6, 2026—Glucagon‐like peptide‐1 receptor agonists (GLP-1 RAs) were shown to be associated with lower risks of death, hospitalization, amputation, and lower-extremity revascularization compared with metformin among adults with type 2 diabetes and peripheral artery disease (PAD), according to the American Heart Association. These findings from an observational analysis study were published by Akiva Rosenzveig, MD, et al in the Journal of the …